Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
October 31, 2024 08:00 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer
October 10, 2024 08:00 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Single-Lead ECG Monitor Market is Projected to Expand at a 9.8% CAGR Through 2034, Says Fact.MR Report
October 02, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Oct. 02, 2024 (GLOBE NEWSWIRE) -- As per a recently published industry report by Fact.MR, the global single-lead ECG monitor market is estimated to reach a valuation of US$ 669...
Cardiac Mapping Market to Surge to USD 5.5 Billion, Exhibiting a 5.8% CAGR from 2024 to 2034: TMR Analysis
July 01, 2024 10:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 01, 2024 (GLOBE NEWSWIRE) -- The global cardiac mapping market stood at US$ 3 billion in 2023, and the global market is...
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
June 06, 2024 08:15 ET
|
Anthos Therapeutics
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
April 22, 2024 11:09 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...
Irregular heartbeat can now be treated more safely and quicker than before
April 08, 2024 12:52 ET
|
Nebraska Medicine
Omaha, Neb., April 08, 2024 (GLOBE NEWSWIRE) -- Nebraska Medicine patient Doris McCann found out something wasn't right with her heart when she got an Apple Watch for Christmas. "I started getting...
Implantable Cardiac Monitor Market Predicted to Achieve 6.6% CAGR and Valued at USD 1.6 Billion by 2031- Report by Transparency Market Research, Inc.
March 18, 2024 10:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, March 18, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The implantable cardiac monitor industry was worth US$ 914.5 million in 2022. By the end of...
Arrhythmia Monitoring Devices Market Size Worth USD 15.33 Billion in 2032 | Emergen Research
January 15, 2024 07:33 ET
|
Emergen Research
Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global arrhythmia monitoring devices market size was USD 7.43 billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the...
Global $12.07 Bn Atrial Fibrillation Markets, 2017-2022, 2022-2027F, 2032F: Analysis, Forecasts and Competitive Landscape
October 26, 2023 04:18 ET
|
Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global atrial fibrillation market is...